4D Molecular Therapeutics, Inc.
FDMT
$4.11
-$0.17-3.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -59.53% | -49.56% | 1.32% | 4.81% | 6.19% |
| Total Depreciation and Amortization | 16.63% | 14.40% | 19.97% | 31.51% | 48.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.01% | 8.13% | 8.75% | 14.08% | 2.20% |
| Change in Net Operating Assets | -14.76% | 1,354.85% | 90.02% | 148.68% | 147.16% |
| Cash from Operations | -77.57% | -54.55% | 8.64% | 15.45% | 12.57% |
| Capital Expenditure | -36.63% | -2.14% | 58.70% | 59.76% | 75.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -352.05% | -447.80% | -505.14% | -318.02% | 2,248.86% |
| Cash from Investing | -361.36% | -465.02% | -535.35% | -337.77% | 778.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 115.04% | 120.86% | 142.53% | 3,281.13% | 4,314.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 183.36% | 123.71% | 100.00% |
| Cash from Financing | 115.04% | 121.53% | 144.00% | 3,354.80% | 4,983.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.71% | -152.66% | -138.47% | 7,480.80% | 295.49% |
